Eledon Pharmaceuticals (NasdaqCM:ELDN) 2026 Conference Transcript

Eledon Pharmaceuticals Conference Call Summary Company Overview - Company: Eledon Pharmaceuticals (NasdaqCM:ELDN) - Focus: Development of immunomodulatory therapies for organ transplantation, particularly kidney and islet cell transplants Key Points Industry and Product Development - Phase 2 BESTOW Study: Significant data generation year in 2025, focusing on CD40 ligand tegoprubart for kidney transplants [3][4] - Progress: Over 100 human transplant patients treated with tegoprubart, showing improved safety compared to tacrolimus, the historical standard of care [4][5] - Islet Cell Transplantation: All six patients in the initial study were able to stop insulin, indicating a functional cure for high-risk Type 1 diabetes [6] Clinical Data and Safety Profile - Safety Improvements: Tegoprubart demonstrated a significantly better safety profile than tacrolimus, with lower incidences of tremors, new-onset diabetes, and other complications [5][13][22] - Efficacy Data: Non-inferiority achieved in the BESTOW study regarding patient survival, organ survival, and rejection rates, although statistical superiority on kidney function was not demonstrated [11][12] - Rejection Rates: Slightly higher rejection rates in the tegoprubart arm, but treated patients showed better kidney function post-rejection [26][28] Regulatory and Future Plans - FDA Engagement: Plans to discuss Phase 3 trial design with the FDA, aiming for a trial size of at least 300 patients with a one-year endpoint [31][42] - Orphan Drug Designation: Recently received for liver transplantation, with plans to initiate a liver IST by the end of the year [8][50] Market Opportunity - Target Market: Approximately 27,000 kidney transplants occur annually in the U.S., with a strategy to capture market share from tacrolimus [43][44] - Pricing Strategy: Potential for competitive pricing given the high costs associated with transplant procedures and dialysis [46] Competitive Landscape - Comparison with Belatacept (Bristol Myers Squibb): Eledon is positioning tegoprubart against tacrolimus rather than belatacept, which has not achieved standard of care status due to various issues [48][49] - Market Share Goals: Aim to replicate tacrolimus's success against cyclosporine, targeting a significant market share [44] Financial Position - Cash Reserves: Ended the previous year with over $130 million, providing a runway into the second quarter of the following year [58][60] Strategic Partnerships - Collaboration Opportunities: Open to partnerships in both islet cell and xenotransplantation technologies, aiming to leverage various advancements in the field [53][56] Additional Insights - Patient Advocacy: Patients have been actively sharing their positive experiences on social media, which may enhance visibility and support for the company's therapies [8] - Long-term Data: Upcoming updates on long-term data from Phase 1b and Phase 2 studies expected in mid to late 2026 [7][12]